Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators.
Adult
Aged
Aged, 80 and over
Disease Progression
Egypt
/ epidemiology
Esophageal and Gastric Varices
/ diagnosis
Female
Gastrointestinal Hemorrhage
/ diagnosis
Hemostatic Techniques
Humans
Hypertension, Portal
/ diagnosis
Length of Stay
Liver Cirrhosis
/ diagnosis
Male
Middle Aged
Patient Discharge
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Young Adult
ALBI score
MELD
cirrhosis
upper gastrointestinal bleeding
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
07
11
2018
revised:
26
01
2019
accepted:
10
03
2019
pubmed:
3
4
2019
medline:
3
3
2020
entrez:
3
4
2019
Statut:
ppublish
Résumé
Upper gastrointestinal bleeding (UGIB) is a serious complication of portal hypertension in cirrhotic patients. The objective of this study is to identify the risk factors for morbidity and mortality occurring after an UGIB attack. A total of 1097 UGIB attacks in 690 patients with liver cirrhosis were studied. Their clinical, laboratory, and endoscopic data were reviewed. Mean age 53.2 ± 10.6 (20-90) years, 78% men and the main cause of liver disease was hepatitis C (94.9%). Complications occurred after 467 attacks (42.6%): hepatic encephalopathy 31.4%, spontaneous bacterial peritonitis 18%, renal impairment 13.2%, and re-bleeding in 7.8%, while 199 patients (18.1%) died. Complications followed 78.4% of bleeding from gastric varices, 75% of post-interventional ulcers, 10.8% of peptic ulcers, and 5.9% of telangiectasias. By univariate analysis: packed red blood cells units transfused, transaminases, Child-Pugh (CP), model of end-stage liver disease (MELD), and albumin-bilirubin (ALBI) scores, beside the presence of hepatocellular carcinoma (HCC), previous hemorrhage in the previous 6 months, and the source of bleeding, were associated with occurrence of complications. By multivariate analysis, independent predictors of complications were CP, MELD, and ALBI scores (odds ratio, 95% confidence interval: 5.63, 3.55-8.93; 1.15, 1.11-1.19; and 2.11, 1.4-3.19, respectively) beside the presence of HCC (4.89, 2.48-9.64). Mortality predictors were packed red blood cells units transfused (1.11, 1.01-1.24), CP (5.1, 1.42-18.25) MELD (1.27, 1.21-1.32) scores, and presence of HCC (6.62, 2.93-14.95). High CP, MELD, and ALBI scores beside the presence of HCC could predict poor outcome of UGIB. In the absence of these risk factors, early discharge could be considered if the source of bleeding is peptic ulcer or telangiectasia.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Upper gastrointestinal bleeding (UGIB) is a serious complication of portal hypertension in cirrhotic patients. The objective of this study is to identify the risk factors for morbidity and mortality occurring after an UGIB attack.
METHODS
METHODS
A total of 1097 UGIB attacks in 690 patients with liver cirrhosis were studied. Their clinical, laboratory, and endoscopic data were reviewed.
RESULTS
RESULTS
Mean age 53.2 ± 10.6 (20-90) years, 78% men and the main cause of liver disease was hepatitis C (94.9%). Complications occurred after 467 attacks (42.6%): hepatic encephalopathy 31.4%, spontaneous bacterial peritonitis 18%, renal impairment 13.2%, and re-bleeding in 7.8%, while 199 patients (18.1%) died. Complications followed 78.4% of bleeding from gastric varices, 75% of post-interventional ulcers, 10.8% of peptic ulcers, and 5.9% of telangiectasias. By univariate analysis: packed red blood cells units transfused, transaminases, Child-Pugh (CP), model of end-stage liver disease (MELD), and albumin-bilirubin (ALBI) scores, beside the presence of hepatocellular carcinoma (HCC), previous hemorrhage in the previous 6 months, and the source of bleeding, were associated with occurrence of complications. By multivariate analysis, independent predictors of complications were CP, MELD, and ALBI scores (odds ratio, 95% confidence interval: 5.63, 3.55-8.93; 1.15, 1.11-1.19; and 2.11, 1.4-3.19, respectively) beside the presence of HCC (4.89, 2.48-9.64). Mortality predictors were packed red blood cells units transfused (1.11, 1.01-1.24), CP (5.1, 1.42-18.25) MELD (1.27, 1.21-1.32) scores, and presence of HCC (6.62, 2.93-14.95).
CONCLUSION
CONCLUSIONS
High CP, MELD, and ALBI scores beside the presence of HCC could predict poor outcome of UGIB. In the absence of these risk factors, early discharge could be considered if the source of bleeding is peptic ulcer or telangiectasia.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1604-1610Informations de copyright
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017; 37: 45-53.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646-649.
Kapsoritakis A, Ntounas E, Makrigiannis E et al. Acute upper gastrointestinal bleeding in central Greece: the role of clinical and endoscopic variables in bleeding outcome. Dig. Dis. Sci. 2009; 54: 333-341.
Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800-809.
Sclerotherapy after first variceal hemorrhage in cirrhosisA randomized multicenter trial. The Copenhagen Esophageal Varices Sclerotherapy Project. N. Engl. J. Med. 1984; 311: 1594-1600.
Moitinho E, Escorsell A, Bandi JC et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117: 626-631.
Chalasani N, Kahi C, Francois F et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am. J. Gastroenterol. 2003; 98: 653-659.
de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol. 2005; 43: 167-1676.
Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-1212.
Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 2008; 57: 814-820.
de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 2015; 63: 743-752.
Pugh R, Murray-lyon I, Dawson J. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646-649.
Wiesner RH, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 2015; 33: 550-558.
Barkun A, Sabbah S, Enns R et al. The Canadian registry on nonvariceal upper gastrointestinal bleeding and endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am. J. Gastroenterol. 2004; 99: 1238-1246.
Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am. J. Gastroenterol. 2012; 107: 247-252.
Berman K, Tandra S, Forssell K et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin. Gastroenterol. Hepatol. 2011; 9: 254-259.
Tromn A, Griga T, Greving I, Hilden H, Schwegler H. Hepatic encephalopathy in patients with cirrhosis and upper GI bleeding. Hepatology 2000; 47: 473-477.
al-Giandan YM. Hepatic encephalopathy in Saudi Arabia. Retrospective analysis of 51 patients. Indian J. Med. Sci. 1992; 46: 69-74.
Lee YY, Tee HP, Mahadeva S. Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. World J. Gastroenterol. 2014; 20: 1790-1796.
Barkun AN, Bardou M, Kuipers EJ et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann. Intern. Med. 2010; 152: 101-113.
Barkun AN, Bhat M, Armstrong D et al. Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. CMAJ 2013; 185: E156-E166.
Chen LS, Lin HC, Hwang SJ, Lee FY, Hou MC, Lee SD. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. J. Gastroenterol. Hepatol. 1996; 11: 59-64.
Kitano S, Dolgor B. Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis? J. Gastroenterol. 2000; 35: 79-86.
Bambha K, Kim WR, Pedersen R et al. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 2008; 57: 814-820.
Hunter SS, Hamdy S. Predictors of early re-bleeding and mortality after acute variceal haemorrhage. Arab J. Gastroenterol. 2013; 14: 63-67.
Reverter E, Tandon P, Augustin S et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 2014; 146: 412-419.
Ma XL, Zhou JY, Gao XH et al. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clin. Chim. Acta 2016; 462: 15-22.
Peng Y, Qi X, Tang S et al. Child-Pugh, MELD, and ALBI scores for predicting the in-hospital mortality in cirrhotic patients with acute-on-chronic liver failure. Expert Rev. Gastroenterol. Hepatol. 2016; 10: 971-980.
Xavier SA, Vilas-Boas R, Boal Carvalho P, Magalhães JT, Marinho CM, Cotter JB. Assessment of prognostic performance of albumin-bilirubin, Child-Pugh, and model for end-stage liver disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding. Eur. J. Gastroenterol. Hepatol. 2018; 30: 652-658.
Zhang W, Liu C, Tan Y et al. Albumin-bilirubin score for predicting post-transplant complications following adult-to-adult living donor liver transplantation. Ann. Transplant. 2018; 23: 639-646.
Trotter JF, Olson J, Lefkowitz J et al. Changes in international normalized ratio (INR) and model for end-stage liver disease (MELD) based on selection of clinical laboratory. Am. J. Transplant. 2007; 7: 1624-1628.
Lisman T, van Leeuwen Y, Adelmeijer J et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int. 2008; 28: 1344-1351.
D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599-612.
Ng WD, Chan YT, Ho KK, Kong CK. Injection sclerotherapy for bleeding esophageal varices in cirrhotic patients with hepatocellular carcinoma. Gastrointest. Endosc. 1989; 35: 69-70.
Kadouchi K, Higuchi K, Shiba M, Okazaki H, Yamamori K, Sasaki E. What are the risk factors for aggravation of esophageal varices in patients with hepatocellular carcinoma? J. Gastroenterol. Hepatol. 2007; 22: 240-246.
Qi X, Su C, Ren W et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: a systematic review of the literature. Clin. Res. Hepatol. Gastroenterol. 2015; 39: 683-691.
Kaya E, Karaca MA, Aldemir D, Ozmen MM. Predictors of poor outcome in gastrointestinal bleeding in emergency department. World J. Gastroenterol. 2016; 22: 4219-4225.
Maggio D, Barkun AN, Martel M, Elouali S, Gralnek IM. Predictors of early rebleeding after endoscopic therapy in patients with nonvariceal upper gastrointestinal bleeding secondary to high-risk lesions. Can. J. Gastroenterol. 2013; 27: 454-458.
Seo YS, Park SY, Kim MY et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014; 60: 954-963.